Cite
IDF23-0223 Targeting miR-122 and miR-4756 mitigates atherogenic events by upregulating Sestrin2 under high glucose condition.
MLA
Rajagopal, A., et al. “IDF23-0223 Targeting MiR-122 and MiR-4756 Mitigates Atherogenic Events by Upregulating Sestrin2 under High Glucose Condition.” Diabetes Research & Clinical Practice, vol. 209, Mar. 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.diabres.2024.111218.
APA
Rajagopal, A., Venkatesan, S., Balasubramanyam, M., Anjana, R. M., Mohan, V., & Manickam, N. (2024). IDF23-0223 Targeting miR-122 and miR-4756 mitigates atherogenic events by upregulating Sestrin2 under high glucose condition. Diabetes Research & Clinical Practice, 209, N.PAG. https://doi.org/10.1016/j.diabres.2024.111218
Chicago
Rajagopal, A., S. Venkatesan, M. Balasubramanyam, R.M. Anjana, V. Mohan, and N. Manickam. 2024. “IDF23-0223 Targeting MiR-122 and MiR-4756 Mitigates Atherogenic Events by Upregulating Sestrin2 under High Glucose Condition.” Diabetes Research & Clinical Practice 209 (March): N.PAG. doi:10.1016/j.diabres.2024.111218.